The U.S. Department of Justice's move to loosen restrictions on some marijuana products and accelerate reclassification of the drug from Schedule I to Schedule III marks the most significant shift in federal cannabis policy in decades - and for Denver, a city that has spent more than 25 years building a regulated marijuana economy, the timing is not incidental. It's urgent.
Why Schedule I Was Always the Wrong Category
Schedule I, under the Controlled Substances Act, is the federal government's most restrictive classification - reserved for substances deemed to have no accepted medical use and a high potential for abuse. Heroin qualifies. LSD qualifies. The argument that marijuana belongs alongside them has grown increasingly difficult to defend as state-level evidence has accumulated over three decades.
Colorado voters legalized medical marijuana in 2000. Recreational sales in Denver began in 2014. What followed was not the social catastrophe opponents predicted. Denver's regulatory authority, the Department of Licensing and Consumer Protection, reports that the city upheld its commitment to preventing increases in youth usage throughout that period - one of the most politically charged metrics in the debate. Meanwhile, the Schedule I designation effectively barred researchers from conducting the kind of rigorous clinical studies that could have settled long-running questions about therapeutic benefits and risks. The classification didn't just restrict commerce. It restricted knowledge.
Schedule III, by contrast, acknowledges accepted medical use and carries substantially reduced regulatory burdens. The reclassification doesn't legalize marijuana at the federal level - that's a separate, thornier question - but it does change the federal government's official posture from "this substance has no legitimate use" to something meaningfully different.
The Tax Problem That Has Been Gutting the Industry
Here's the thing that gets lost in the broad-strokes coverage of rescheduling: the most immediate, concrete consequence for cannabis businesses isn't about what they can sell or to whom. It's about what they can deduct.
Section 280E of the federal tax code prohibits businesses trafficking in Schedule I or II substances from claiming standard business deductions - expenses like payroll, rent, utilities, and marketing that any other retailer writes off as a matter of course. For cannabis operators, this has meant effective tax rates that can exceed 70 percent of gross profit. Not revenue. Profit. The provision was originally written to prevent cocaine dealers from deducting their costs. It has spent the last decade applying to state-licensed, inspected, and taxed dispensaries operating fully within the law.
Reclassification to Schedule III would remove marijuana from 280E's reach. That single change - access to standard business deductions - could determine whether hundreds of licensed operators survive the current industry downturn or close.
Denver's Cannabis Sector Is Contracting. Fast.
The numbers are stark. Active licenses for medical marijuana stores in Denver fell from 152 in April 2022 to 83 in 2026 - a drop of more than 45 percent in four years. Medical cultivation licenses declined from 188 to 75 over the same period. Licenses for infused product manufacturers, which produce edibles and similar goods, fell from 84 to 51.
This is an industry in recession, to use the word Executive Director Molly Duplechian chose deliberately. Operators face a market where legal product competes with a persistent illicit market - one that carries none of the regulatory costs, tax obligations, or compliance burdens of licensed businesses. When the legal side of the market also carries a 280E penalty that the illicit side obviously doesn't, the structural disadvantage compounds. The result is visible in Denver's licensing data: consolidation, closures, and a shrinking formal sector.
Tax relief won't resolve every pressure facing the industry. Oversupply, price compression, and competition from adjacent states and unregulated sources all play a role. But removing a punitive federal tax provision that applies to no other legitimate retail sector would, at minimum, stop actively penalizing compliance.
What Rescheduling Doesn't Fix - and What Comes Next
Reclassification to Schedule III is not the same as comprehensive federal legalization, and the distinction matters. Banking access remains complicated for cannabis businesses in states without specific state-level protections. Interstate commerce is still prohibited, meaning legal markets in Colorado, California, and Oregon remain walled off from each other regardless of federal scheduling. Employers in federally regulated industries can still enforce zero-tolerance drug policies. Criminal records stemming from marijuana convictions remain unaddressed.
Duplechian's statement gestures toward this gap, framing rescheduling as a "first step" and calling on federal lawmakers to consider additional measures - specifically measures that could reduce the illicit market, which continues to undercut licensed operators on price and accessibility.
What's striking here is the source of that call. This isn't a cannabis industry lobbying group or a legalization advocacy organization speaking. This is Denver's own regulatory office, the body responsible for licensing and compliance, making a policy argument grounded in 25 years of observable outcomes. That institutional voice carries weight that activists and trade groups cannot replicate.
Whether Congress moves beyond rescheduling - on banking, on social equity provisions for communities disproportionately affected by enforcement, on interstate commerce - remains genuinely uncertain. Rescheduling by DOJ action sidesteps the legislative process, which means the broader architecture of federal cannabis policy still requires congressional action to change. That is, historically, where cannabis reform has stalled. The reclassification is real progress. The harder work is still ahead.
